255 related articles for article (PubMed ID: 21304503)
41. [Gemcitabine: from preclinic to clinic passing by pharmacokinetics].
Lokiec F; Lansiaux A
Bull Cancer; 2007; 94 Spec No Actualites():S85-9. PubMed ID: 17845976
[TBL] [Abstract][Full Text] [Related]
42. Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma.
Ogawa M; Hori H; Ohta T; Onozato K; Miyahara M; Komada Y
Clin Cancer Res; 2005 May; 11(9):3485-93. PubMed ID: 15867251
[TBL] [Abstract][Full Text] [Related]
43. A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.
Yang MY; Lee YB; Ahn CH; Kaye J; Fine T; Kashi R; Ohne O; Smid K; Peters GJ; Kim DJ
Anticancer Res; 2014 Dec; 34(12):6951-9. PubMed ID: 25503121
[TBL] [Abstract][Full Text] [Related]
44. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
[TBL] [Abstract][Full Text] [Related]
45. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
[TBL] [Abstract][Full Text] [Related]
46. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
47. PharmGKB summary: gemcitabine pathway.
Alvarellos ML; Lamba J; Sangkuhl K; Thorn CF; Wang L; Klein DJ; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Nov; 24(11):564-74. PubMed ID: 25162786
[No Abstract] [Full Text] [Related]
48. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Dumez H; Louwerens M; Pawinsky A; Planting AS; de Jonge MJ; Van Oosterom AT; Highley M; Guetens G; Mantel M; de Boeck G; de Bruijn E; Verweij J
Anticancer Drugs; 2002 Jul; 13(6):583-93. PubMed ID: 12172503
[TBL] [Abstract][Full Text] [Related]
49. Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene.
Eliopoulos N; Beauséjour C; Momparler RL
Prog Exp Tumor Res; 1999; 36():124-42. PubMed ID: 10386070
[No Abstract] [Full Text] [Related]
50. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
Li L; Fridley BL; Kalari K; Jenkins G; Batzler A; Weinshilboum RM; Wang L
PLoS One; 2009 Nov; 4(11):e7765. PubMed ID: 19898621
[TBL] [Abstract][Full Text] [Related]
51. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
Li H; Wang X; Wang X
Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
[TBL] [Abstract][Full Text] [Related]
53. Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.
Delaloge S; Llombart A; Di Palma M; Tourani JM; Turpin F; Ni L; Forgue ST; Le Chevalier T
Am J Clin Oncol; 2004 Jun; 27(3):289-93. PubMed ID: 15170150
[TBL] [Abstract][Full Text] [Related]
54. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Serdjebi C; Seitz JF; Ciccolini J; Duluc M; Norguet E; Fina F; Lacarelle B; Ouafik L; Dahan L
Pharmacogenomics; 2013 Jul; 14(9):1047-51. PubMed ID: 23837479
[TBL] [Abstract][Full Text] [Related]
55. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
Mercier C; Raynal C; Dahan L; Ortiz A; Evrard A; Dupuis C; Blesius A; Duluc M; Franceschini F; Giacometti S; Salas S; Milano G; Favre R; Seitz JF; Ciccolini J
Pharmacogenet Genomics; 2007 Oct; 17(10):841-4. PubMed ID: 17885621
[TBL] [Abstract][Full Text] [Related]
56. Deciphering the role of Enterococcus faecium cytidine deaminase in gemcitabine resistance of gallbladder cancer.
Jiang L; Zhang L; Shu Y; Zhang Y; Gao L; Qiu S; Zhang W; Dai W; Chen S; Huang Y; Liu Y
J Biol Chem; 2024 Apr; 300(4):107171. PubMed ID: 38492776
[TBL] [Abstract][Full Text] [Related]
57. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Gusella M; Pasini F; Bolzonella C; Meneghetti S; Barile C; Bononi A; Toso S; Menon D; Crepaldi G; Modena Y; Stievano L; Padrini R
Br J Clin Pharmacol; 2011 Mar; 71(3):437-44. PubMed ID: 21284703
[TBL] [Abstract][Full Text] [Related]
58. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
[TBL] [Abstract][Full Text] [Related]
59. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
Neff T; Blau CA
Exp Hematol; 1996 Sep; 24(11):1340-6. PubMed ID: 8862446
[TBL] [Abstract][Full Text] [Related]
60. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
